Praxsyn Corp (PXYN)

[SeanBoy]

The next step should likely be another shareholder's newsletter, followed up by getting current on filings.

They have been there and done that, over a year ago, lol. Don't take my word for it, just read below what they said, lol.

IRVINE, Calif., June 21, 2016 -- Praxsyn Corporation (OTC:PXYN) published a letter on April 15, 2016 to its shareholders from Greg Sundem, its Chairman and Chief Executive Officer.  This letter is from Mr. Sundem to update the Company’s shareholders as to the Company’s business and operations as of this date. 
Dear Shareholders,
I wanted to take an opportunity to update you as to our delay in filing our Annual Report on Form 10-K for the Fiscal Year ended December 31, 2015, and our Quarterly Report on Form 10-Q for the Quarter ended March 31, 2016.  Regrettably, we are delayed in our filings due to being in the final phase of our business reorganization and restructure of our operations.  I anticipate that the strong measures that I have instituted will have an overall positive effect on the Company. 
To that end, since my last letter to the shareholders, we have:
Commenced taking new prescriptions that do not require any upfront marketing costs, allowing us to greatly reduce the front end cost of new receivables.
I, together with our CFO/COO, and General Counsel/Secretary have deferred salaries until the Company’s overall cash flow has improved, however, as the rate of collections on our existing accounts receivable is rapidly increasing, this deferral is projected to end within the next few payroll cycles.
Commenced negotiations to restructure our long term debt.
Commenced the planning of establishing our first pharmacy outside the state of California.
In the next few weeks, we plan to
Publish our Form 10-K for the Fiscal Year ended December 31, 2015, and shortly thereafter publish our Form 10-Q for the Quarter ended March 31, 2016.
Commence our California sales of workers’ compensation cases that are pre-approved.
Commence auxiliary sales into out of state markets with what we believe will have substantially faster payment on claims.
In order to further increase our shareholder value, we are still planning to:
Acquire or become an FDA approved and fully licensed drug manufacturing facility so that we may offer products that we may sell to other pharmacies, hospitals and clinics.
Pursue accretive acquisitions of laboratories, and other medical providers who enjoy rapid claims payments.
Further diversify into additional medical industry profit centers.
Finally, we plan to vastly improve communications with our shareholders. To this end we plan to:
Frequently release company news through press releases.
Hold investor teleconferences or comprehensive press releases along with the release of each subsequent Annual and Quarterly filing.
Hire a staff member only dedicated to Investor Relations